lencana Anda Rentang 52M $146–$303 92% of range Peringkat Analis BUY 23 analysts Target Harga $305 +5% upside P/E -60.5 ROE -7.7% Margin Laba Bersih -6.0%

CRL Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $290.19
Kapitalisasi Pasar (MRQ) $13.85B
P/E (TTM) -60.5
EPS (TTM) $-4.80
Pendapatan (TTM) $4.00B
ROE (TTM) -7.7%
D/E Utang/Ekuitas (MRQ) 0.0
Rentang 52M $146–$303

CRL Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Tentang Charles River Laboratories International, Inc. Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.

Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.

As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

History

Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.

In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.

The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.

Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.

In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.

In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.

In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.

Acquisitions

In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.

Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.

In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.

In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.

From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.

In July 2015, the company announced it would acquire Celsis International for $212 million.

In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.

In August 2017, the business announced it would acquire Brains On-Line.

In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.

In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.

In August 2020, the company announced it would acquire Cellero for $38 million in cash.

In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.

In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.

In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.

In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.

In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.

In April 2022, the company announced it would acquire Explora BioLabs.

In January 2023, the business announced it would acquire SAMDI Tech, Inc.

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriLife Sciences Tools & Services karyawan18.300 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$4.02B
2016-12-31 → 2025-12-27
EPS$-2.91
2016-12-31 → 2025-12-27
Arus Kas Bebas$518M
2016-12-31 → 2025-12-27
Margin bersih-6.0%
2016-12-31 → 2025-12-27
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun CRL rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) -60.5rata-rata 5T ≈191.6 ≈191.6 · ·
P/S (TTM) 3.5rata-rata 5T ≈3.2 ≈3.2 4.9 Kurang nilai
P/B (MRQ) 4.9rata-rata 5T ≈4.1 ≈4.1 3.6 Nilai wajar
EV / EBITDA 32.8rata-rata 5T ≈16.9 ≈16.9 25.4 Kurang nilai
Harga / FCF (TTM) 37.4rata-rata 5T ≈28.8 ≈28.8 · ·
Harga / Arus Kas (TTM) 23.8rata-rata 5T ≈17.3 ≈17.3 26.2 Kurang nilai
EV / Revenue (EV / Pendapatan) 3.5rata-rata 5T ≈3.1 ≈3.1 · ·
EV / FCF 27.1rata-rata 5T ≈28.3 ≈28.3 · ·
Harga / Nilai Buku Berwujud (MRQ) 5.4 · · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata 8.9%
Laporan Berikutnya Nov 03, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Agu 12, 2026 $3.02 $2.76 9.2%
31 Maret 2026 $2.06 $1.96 5.0%
31 Des. 2025 $2.39 $2.37 0.98%
30 Sep. 2025 $2.43 $2.36 2.9%
30 Juni 2025 $3.12 $2.52 23.7%
31 Maret 2025 $2.34 $2.10 11.4%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 15
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B$1.36B$1.30B
Cost of Revenue ········$290M$277M$264M$266M
SG&A Expense $743M$751M$748M$665M$620M$529M$518M$444M$371M$365M$300M$269M
Operating Income $25M$227M$617M$651M$590M$433M$351M$331M$288M$238M$206M$178M
Interest Expense ··$137M$59M$74M$86M$61M$64M$30M$28M$15M$12M
Interest Income $5M$9M$5M$780.0K$652.0K$834.0K$2M$812.0K$690.0K$1M$1M$1M
Other Non-op $-23M$-17M$96M$31M$-36M$100M$12M$13M$38M$12M$3M$11M
Pretax Income $-100M$93M$581M$623M$481M$447M$304M$282M$297M$223M$195M$178M
Income Tax $43M$68M$101M$130M$82M$82M$50M$54M$171M$67M$43M$48M
Net Income $-144M$22M$475M$486M$391M$364M$252M$226M$123M$155M$149M$127M
EPS (Basic) $-2.91$0.20$9.27$9.57$7.77$7.35$5.17$4.72$2.60$3.29$3.21$2.72
EPS (Diluted) $-2.91$0.20$9.22$9.48$7.60$7.20$5.07$4.62$2.54$3.23$3.13$2.66
Shares (Basic) 49,564,00051,380,00051,227,00050,812,00050,293,00049,550,00048,730,00047,947,00047,481,00047,014,00046,496,00046,627,000
Shares (Diluted) 49,564,00051,628,00051,451,00051,301,00051,425,00050,611,00049,693,00049,018,00048,564,00047,958,00047,634,00047,558,000
EBITDA $428M$589M$931M$955M$855M$668M$549M$493M$419M$364M$301M$274M
Neraca 30
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $214M$195M$277M$234M$241M$228M$238M$195M$164M$118M$118M$160M
Short-term Investments ····$1M$1M$941.0K$885.0K$28M$4M$21M·
Receivables $709M$721M$780M$752M$643M$618M$514M$472M$430M$364M$270M$258M
Inventory $299M$279M$380M$256M$199M$186M$161M$128M$115M$96M$94M$89M
Prepaid Expense $129M$106M$83M$108M$97M$73M$56M$49M$81M$45M$47M$45M
Other Current Assets ·····$0$300.0K$300.0K$0$45M$47M$73M
Current Assets $1.45B$1.40B$1.61B$1.44B$1.27B$1.20B$1.02B$898M$827M$657M$559M$579M
PP&E (Net) $1.66B$1.60B$1.64B$1.47B$1.29B$1.12B$1.04B$933M$782M$756M$678M$677M
PP&E (Gross) $3.19B$3.06B$2.98B$2.63B$2.39B$2.21B$2.02B$1.81B$1.58B$1.46B$1.32B$1.33B
Accum. Depreciation $1.54B$1.45B$1.34B$1.16B$1.10B$1.09B$978M$874M$801M$706M$645M$655M
Goodwill $2.76B$2.85B$3.10B$2.85B$2.71B$1.81B$1.54B$1.25B$805M$788M$439M$321M
Intangibles $340M$723M$864M$955M$1.06B$788M$689M$611M$370M$394M$281M$281M
Other Non-current Assets $293M$278M$309M$148M$152M$353M$213M$144M$124M$88M$72M$73M
Total Assets $7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B$2.07B$1.87B
Accounts Payable $149M$140M$169M$206M$198M$122M$111M$66M$78M$68M$37M$34M
Accrued Liabilities $270M$232M$228M$220M$229M$150M$139M$107M$90M$84M$89M$67M
Current Liabilities $1.12B$994M$1.06B$1.09B$1.03B$840M$710M$558M$464M$430M$312M$295M
Capital Leases $434M$484M$419M$390M$253M$156M$116M·····
Deferred Tax $95M$107M$191M$216M$240M$217M$167M$144M$90M$56M$48M$23M
Other Non-current Liabilities $138M$195M$223M$175M$243M$205M$183M$179M$195M$159M$89M$100M
Total Liabilities $3.92B$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B$1.86B$1.30B$1.17B
Long-term Debt ·······$1.61B$1.09B$1.18B$814M$717M
Total Debt $166.0K$155.0K$3M$1M$101.0K$47M$36M$1.65B$1.12B$1.21B$836M$754M
Common Stock $492.0K$511.0K$513.0K$509.0K$505.0K$498.0K$489.0K$482.0K$875.0K$863.0K$855.0K$845.0K
Retained Earnings $1.39B$1.81B$1.89B$1.43B$981M$625M$280M$42M$289M$165M$11M$-139M
Treasury Stock $0$0$0$0$0$0$0$55.0K$1.66B$1.55B$1.54B$1.42B
AOCI $-172M$-317M$-196M$-262M$-165M$-139M$-178M$-173M$-145M$-254M$-136M$-74M
Stockholders' Equity $3.16B$3.46B$3.60B$2.98B$2.53B$2.11B$1.63B$1.32B$1.05B$837M$733M$672M
Liabilities + Equity $7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B$2.07B$1.87B
Shares Outstanding 49,217,00051,141,00051,338,00050,944,00050,480,00049,767,00048,936,00048,209,00047,402,00047,363,00046,698,00047,327,000
Arus Kas 18
Metrik Tren 202520242023202220212020201920182017201620152014
D&A $403M$362M$314M$304M$266M$235M$198M$162M$131M$127M$95M$96M
Stock-based Comp $71M$70M$72M$74M$71M$56M$57M$47M$44M$44M$40M$31M
Deferred Tax $-75M$-67M$-51M$-33M$-20M$2M$-21M$-10M$28M$3M$4M$9M
Amort. of Intangibles $179M$138M$137M$147M$125M$112M$90M$65M$41M$42M$24M$26M
Restructuring $100M$107M$30M$8M$7M$13M$14M$10M$5M$18M$8M$8M
Other Non-cash $483M$348M$-126M$-211M$53M$-111M$-5M$16M$-8M$-28M$-395.0K·
Operating Cash Flow $738M$735M$684M$620M$761M$547M$481M$441M$318M$317M$307M$252M
CapEx $219M$233M$319M$325M$229M$167M$141M$140M$82M$55M$63M$57M
Investing Cash Flow $-209M$-245M$-563M$-608M$-1.44B$-602M$-682M$-955M$-73M$-693M··
Debt Issued $1.23B$1.08B$776M$2.95B$6.95B$2.23B$3.36B$2.76B$237M$1.04B··
Net Debt Issued $1.23B$1.08B$776M$2.95B$6.95B$2.23B$3.36B$2.76B····
Stock Repurchased $361M$119M$24M$39M$41M$24M$18M$14M$107M$12M$117M$122M
Net Stock Activity $-361M$-119M$-24M$-39M$-41M$-24M$-18M$-14M$-107M$-12M$-117M$-122M
Financing Cash Flow $-537M$-551M$-86M$-42M$673M$47M$232M$558M$-208M$381M··
Net Change in Cash $10M$-79M$43M$-5M$13M$-7M$43M$31M$46M$-69.0K$-43M$4M
Taxes Paid $120M$126M$90M$76M$75M$60M$54M$68M····
Free Cash Flow $518M$502M$365M$295M$532M$380M$340M$301M$236M$245M$225M$195M
Levered FCF ··$252M$248M$471M$309M$290M$250M$223M$226M$213M$186M
Profitabilitas 7
Metrik Tren 202520242023202220212020201920182017201620152014
Operating Margin 0.63%5.6%14.9%16.4%16.7%14.8%13.4%14.6%15.5%14.1%15.1%13.7%
Net Margin -3.6%0.55%11.5%12.2%11.0%12.5%9.6%10.0%6.6%9.2%10.9%·
Pretax Margin -2.5%2.3%14.1%15.7%13.6%15.3%11.6%12.4%16.0%13.3%14.3%13.7%
EBITDA Margin 10.7%14.5%22.6%24.0%24.2%22.8%20.9%21.8%22.5%21.6%22.1%21.1%
ROA -2.0%0.28%6.0%6.7%6.2%7.1%5.9%6.7%4.4%6.5%7.6%·
ROE -4.4%0.63%14.4%17.6%16.8%19.4%17.1%19.2%13.1%19.7%21.2%·
ROIC 1.1%1.8%14.2%17.3%19.3%16.4%17.6%9.0%5.6%8.1%10.2%9.1%
Likuiditas & Solvabilitas 5
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 1.31.41.51.31.21.41.41.61.81.51.82.0
Quick Ratio 0.80.91.00.90.91.01.11.21.31.11.21.4
Debt / Equity 0.00.00.00.00.00.00.01.31.11.41.11.1
LT Debt / Equity ·······1.21.01.41.11.1
Interest Coverage ··4.511.08.05.05.85.29.78.613.714.9
Efisiensi 3
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.50.50.50.50.60.60.60.70.70.70.70.7
Inventory Turnover ········2.72.92.93.0
Receivables Turnover 5.65.45.45.75.65.25.35.04.75.35.25.4
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $64.30$67.69$70.06$58.42$50.21$42.49$33.40$27.33$22.05$17.67$15.70$14.20
Revenue / Share $81.01$78.45$80.26$77.50$68.84$57.77$52.75$46.23$38.25$35.06··
Cash Flow / Share $14.88$14.23$13.29$12.08$14.79$10.80$9.68$9.00$6.55$6.26··
Cash / Share $4.34$3.81$5.39$4.59$4.78$4.59$4.86$4.05$3.46$2.48$2.53$3.38
EPS (TTM) $-2.91$0.20$9.22$9.48$7.60$7.20$5.07$4.62$2.54$3.23$3.13$2.66
Tingkat Pertumbuhan 7
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY -0.85%-1.9%3.9%12.3%21.1%·······
Revenue CAGR 3Y 0.33%4.6%12.2%·········
Revenue CAGR 5Y 6.6%···········
EPS YoY ·-97.8%-2.7%24.7%5.6%·······
EPS CAGR 3Y ·-70.3%8.6%·········
Net Income YoY ·-95.3%-2.4%24.4%7.3%·······
Net Income CAGR 3Y ·-61.6%9.2%·········
Valuasi (TTM) 14
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B$1.36B$1.30B
Net Income TTM $-144M$22M$475M$486M$391M$364M$252M$226M$123M$155M$149M$127M
Market Cap $10.02B$9.52B$12.14B$11.10B$18.64B$12.53B$7.43B$5.39B$5.19B$3.61B$3.74B$3.04B
Enterprise Value $9.81B$9.33B$11.86B$10.87B$18.40B$12.34B$7.23B$6.84B$6.12B$4.70B$4.46B$3.64B
P/E -70.0930.825.623.048.635.030.024.243.123.625.624.2
P/S 2.52.42.92.85.34.32.82.42.82.12.72.3
P/B 3.22.83.43.77.45.94.54.15.04.35.14.5
P / Tangible Book 166.0···········
P / Cash Flow 13.613.017.717.924.522.915.512.216.312.013.012.1
P / FCF 19.319.033.237.635.033.021.817.922.014.716.615.6
EV / EBITDA 22.915.812.711.421.518.513.213.914.612.914.813.3
EV / FCF 18.918.632.536.934.632.521.222.726.019.219.818.6
EV / Revenue 2.42.32.92.75.24.22.83.03.32.83.32.8
Earnings Yield -1.4%0.11%3.9%4.3%2.1%2.9%3.3%4.1%2.3%4.2%3.9%4.1%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-272024-12-282023-12-302022-12-312021-12-25
Pendapatan $4.02B $4.05B $4.13B $3.98B $3.54B
Margin Operasi % 0.63% 5.6% 14.9% 16.4% 16.7%
Laba Bersih $-144M $22M $475M $486M $391M
EPS Dilusian $-2.91 $0.20 $9.22 $9.48 $7.60

Pemilik institusional (13F) 607 pengaju · $13.6B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 607
Nilai yang dipegang $13.6B
Posisi baru 74
Posisi yang keluar 62
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
74 (-17 vs Kuartal sebelumnya) 62 (-19 vs Kuartal sebelumnya) 193 (0 vs Kuartal sebelumnya) 204 (+13 vs Kuartal sebelumnya) +2.8M

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
VANGUARD GROUP INC $1.174.373.670 5.887.175 8,66% Saham
FMR LLC $961.533.236 4.239.752 7,09% Saham
BlackRock, Inc. $861.475.349 3.798.560 6,35% Saham
VANGUARD CAPITAL MANAGEMENT LLC $714.227.026 3.149.288 5,26% Saham
Invesco Ltd. $676.919.391 2.984.785 4,99% Saham
HARRIS ASSOCIATES L P $508.269.048 2.241.144 3,75% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $501.427.927 2.210.979 3,70% Saham
Allspring Global Investments Holdings, LLC $436.473.035 1.905.247 3,22% Saham
STATE STREET CORP $422.800.968 1.864.284 3,12% Saham
DIMENSIONAL FUND ADVISORS LP $373.848.597 1.648.450 2,76% Saham
ARIEL INVESTMENTS, LLC $341.587.697 1.506.185 2,52% Saham
GEODE CAPITAL MANAGEMENT, LLC $295.598.099 1.305.738 2,18% Saham
WELLINGTON MANAGEMENT GROUP LLP $292.210.525 1.288.463 2,15% Saham
CITADEL ADVISORS LLC $270.696.771 1.193.601 2,00% Saham
BANK OF AMERICA CORP /DE/ $265.930.779 1.172.586 1,96% Saham
EARNEST PARTNERS LLC $254.007.295 1.120.011 1,87% Saham
AMERIPRISE FINANCIAL INC $199.834.979 881.189 1,47% Saham
NEUBERGER BERMAN GROUP LLC $195.633.630 862.704 1,44% Saham
SEI INVESTMENTS CO $184.499.540 813.530 1,36% Saham
MORGAN STANLEY $181.542.851 800.487 1,34% Saham
Clearbridge Investments, LLC $177.185.527 781.276 1,31% Saham
COOKE & BIELER LP $171.369.328 755.630 1,26% Saham
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ $157.642.604 682.173 1,16% Saham
VICTORY CAPITAL MANAGEMENT INC $150.762.735 664.768 1,11% Saham
UBS Group AG $146.675.752 646.747 1,08% Saham
GOLDMAN SACHS GROUP INC $145.100.822 639.803 1,07% Saham
MILLENNIUM MANAGEMENT LLC $110.324.717 486.462 0,81% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $106.061.291 467.663 0,78% Saham
BANK OF MONTREAL /CAN/ $104.270.783 459.768 0,77% Saham
NORTHERN TRUST CORP $101.169.205 446.092 0,75% Saham
Gotham Asset Management, LLC $98.233.181 433.146 0,72% Saham
Amundi $93.528.650 412.402 0,69% Saham
NORGES BANK $83.921.372 370.040 0,62% Saham
MARSHALL WACE, LLP $77.787.835 342.995 0,57% Saham
Iron Triangle Partners LP $75.748.141 379.728 0,56% Saham
CITIGROUP INC $71.714.853 316.217 0,53% Saham
BNP PARIBAS FINANCIAL MARKETS $69.108.583 304.725 0,51% Saham
Bank of New York Mellon Corp $69.054.385 304.486 0,51% Saham
Boston Trust Walden Corp $65.523.486 288.917 0,48% Saham
JPMORGAN CHASE & CO $65.085.033 286.317 0,48% Saham
ALLIANCEBERNSTEIN L.P. $64.615.913 374.585 0,48% Saham
SNYDER CAPITAL MANAGEMENT L P $63.899.443 281.756 0,47% Saham
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $63.174.169 278.558 0,47% Saham
DEUTSCHE BANK AG\ $62.723.084 276.569 0,46% Saham
VANGUARD FIDUCIARY TRUST CO $61.384.115 270.665 0,45% Saham
PRIMECAP MANAGEMENT CO/CA/ $60.523.448 266.870 0,45% Saham
RAYMOND JAMES FINANCIAL INC $58.234.910 256.779 0,43% Saham
Meridiem Capital Partners LP $56.012.367 246.979 0,41% Saham
Alyeska Investment Group, L.P. $53.295.650 235.000 0,39% Saham
LOOMIS SAYLES & CO L P $50.725.593 223.668 0,37% Saham

Tampilkan semua 607 pemilik institusional →

Aktivis & pemilik 5%+ 6 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
JANA PARTNERS LLC ×4 pengajuan 4 Agu 2011 · Pengajuan awal · SEC
Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 pengajuan 9 Feb. 2011 · Pengajuan awal · SEC
Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 pengajuan 7 Des. 2010 · Pengajuan awal · SEC
Orang pelapor yang tidak diungkapkan 16 Juni 2010 · Pengajuan awal · SEC
Orang pelapor yang tidak diungkapkan 7 Juni 2010 · Pengajuan awal Investasi pasif SEC
Charles River Laboratories International, Inc. IRS No. 061397316 5 Mei 2010 · Pengajuan awal Kampanye dewan SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 57 orang dalam · 23 pejabat · 29 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Birgit Girshick Chief Executive Officer 19 Agu 2026 G 35.485 0 1 $-1.819.350
Glenn Coleman EVP & Chief Financial Officer 30 Sep. 2026 P 27.762 1 0 $2.974
Flavia Pease Corporate Executive VP & CFO 31 Mei 2025 F 17.297 0 0 $0
David Ross Smith Corporate Executive VP & CFO 3 Maret 2022 M 25.819 0 0 $0
Davide Molho President & COO 24 Juli 2018 M 17.155 0 0 $0
Shannon M Parisotto CEVP, Disc & Safety Assessment 19 Agu 2026 M 4.807 0 3 $-2.965.466
Mark Mintz EVP, Chief Information Officer 31 Mei 2026 F 9.546 0 0 $0
William D Barbo Corporate Executive VP & CCO 7 Nov. 2024 G 23.337 0 0 $0
John W Kuo CEVP General Counsel & CCO 1 Juni 2020 A 3.171 0 0 $0
David P Johst Corporate Executive VP 29 Mei 2020 A 224.478 0 0 $0
John J Crowley SVP, Chief Accounting Officer 1 Okt. 2016 F 5.599 0 0 $0
Nancy Gillett Corporate Executive VP 2 Maret 2016 S 11.034 0 0 $0
Jorg Geller Corporate Executive VP 25 Feb. 2015 M 14.094 0 0 $0
RENAUD REAL H Corp. Executive VP 11 Agu 2010 F 74.390 0 0 $0
Christopher Berthoux Executive Vice President 26 Feb. 2010 A 31.897 0 0 $0
Joanne P Acford Corp. Sr VP, GC and Corp. Sec 11 Agu 2007 F 37.109 0 0 $0
David J Elliott Officer 29 Juni 2007 M 11.750 0 0 $0
Cheri L Walker Corporate Senior VP 1 Mei 2007 A 6.262 0 0 $0
Stephanie B Wells Senior Vice President 2 April 2007 A 11.500 0 0 $0
Nicholas Ventresca Senior Vice President 2 April 2007 F 12.713 0 0 $0
John C Ho Senior Vice President 23 Feb. 2007 A 12.710 0 0 $0
Brian Bathgate Corporate Vice President 27 Feb. 2006 S 16.134 0 0 $0
Alastair Stuart Mcewan Corporate VP 23 Des. 2004 M 8.000 0 0 $0
James C Foster Direktur 25 Agu 2026 M 31.596 0 3 $-34.844.875
Nancy C Andrews Direktur 18 Agu 2026 M 1.438 0 1 $-163.443
Steven Barg Direktur 2 Juni 2026 A 3.287 0 0 $0
Reshema Kemps-Polanco Direktur 8 Mei 2026 A 4.563 0 0 $0
George Llado Direktur 8 Mei 2026 A 6.702 0 0 $0
Abraham Ceesay Direktur 8 Mei 2026 A 2.384 0 0 $0
Mark J Enyedy Direktur 8 Mei 2026 A 2.384 0 0 $0
Paul W Graves Direktur 8 Mei 2026 A 2.384 0 0 $0
Craig B. Thompson Direktur 8 Mei 2026 A 3.851 0 0 $0
Martin Mackay Direktur 8 Mei 2026 A 17.137 0 0 $0
Virginia M Wilson Direktur 8 Mei 2026 A 6.349 0 0 $0
George Massaro Direktur 15 Mei 2025 S 5.575 0 0 $0
Richard F Wallman Direktur 7 Nov. 2024 S 0 0 0 $0
Deborah Turner Kochevar Direktur 13 Mei 2024 A 7.894 0 0 $0
Robert J Bertolini Direktur 13 Mei 2024 A 32.802 0 0 $0
Richard C Reese Direktur 15 Mei 2023 A 65.541 0 0 $0
George M Milne JR Direktur 7 Mei 2021 A 29.079 0 0 $0
Stephen D Chubb Direktur 23 Feb. 2021 M 40.529 0 0 $0
Jean-Paul Mangeolle Direktur 22 Mei 2019 A 3.886 0 0 $0
William Waltrip Direktur 5 Des. 2012 S 21.830 0 0 $0
Samuel O Thier MD Direktur 9 Mei 2012 A 18.230 0 0 $0
Douglas E Rogers Direktur 7 Mei 2010 A 12.859 0 0 $0
Nancy T Chang Direktur 7 Mei 2010 A 31.010 0 0 $0
Linda Mcgoldrick Direktur 13 Feb. 2006 A · 0 0 $0
Walter S Nimmo Direktur 25 Feb. 2005 S 149.447 0 0 $0
John Urquhart Direktur 17 Feb. 2005 A 11.738 0 0 $0
Louise S Mccrary Direktur 17 Feb. 2005 A · 0 0 $0
Robert Cawthorn Direktur 2 Juni 2004 G 278.600 0 0 $0
Joseph W Laplume · 10 Agu 2026 G 31.041 1 1 $-61.124
Victoria L Creamer · 6 Agu 2026 M 30.051 0 1 $-1.083.030
Michael Gunnar Knell · 6 Agu 2026 M 11.852 0 9 $-1.730.250
Thomas F Ackerman · 29 Feb. 2016 F 111.346 0 0 $0
Dennis R Shaughnessy · 29 Nov. 2004 G 35.511 0 0 $0
Michael F Ankcorn · 4 Nov. 2004 S 0 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 106 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
EPSB · Harbor ETF Trust 2,15% 443 NS 31 Juli 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,73% 51.248 SH 1 Okt. 2026 Harian
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1,71% 5.092 NS 31 Juli 2026 N-PORT
EPSV · Harbor ETF Trust 1,59% 415 NS 31 Juli 2026 N-PORT
EPMV · Harbor ETF Trust 1,44% 291 NS 31 Juli 2026 N-PORT
ALTL · Pacer Funds Trust 1,09% 4.303 NS 31 Juli 2026 N-PORT
IBB · iShares Trust 0,96% 363.741 SH 11 Sep. 2026 Harian
LSEQ · Harbor ETF Trust 0,93% 614 NS 31 Juli 2026 N-PORT
HIBL · Direxion Shares ETF Trust 0,74% 2.375 NS 31 Juli 2026 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 0,69% 22.191 SH 1 Okt. 2026 Harian
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,66% 259 NS 31 Juli 2026 N-PORT
PALC · Pacer Funds Trust 0,61% 5.509 NS 31 Juli 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,49% 12.141 NS 31 Juli 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,45% 6.439 NS 31 Juli 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0,44% 24.918 SH 1 Okt. 2026 Harian
FFSM · FIDELITY COVINGTON TRUST 0,40% 25.814 NS 31 Juli 2026 N-PORT
DFAT · Dimensional ETF Trust 0,34% 209.615 NS 31 Juli 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,28% 7.783 NS 31 Juli 2026 N-PORT
ESML · iShares Trust 0,24% 25.082 SH 11 Sep. 2026 Harian
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,24% 20.898 NS 31 Juli 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,24% 25.378 NS 31 Juli 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,23% 13.626 NS 31 Juli 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0,23% 701.498 SH 19 Agu 2026 Harian
DFAS · Dimensional ETF Trust 0,22% 147.648 NS 31 Juli 2026 N-PORT
RSP · Invesco Exchange-Traded Fund Trust 0,22% 702.813 SH 1 Okt. 2026 Harian
IYH · iShares Trust 0,22% 28.670 SH 11 Sep. 2026 Harian
SMMD · iShares Trust 0,19% 26.152 SH 11 Sep. 2026 Harian
IXJ · iShares Trust 0,17% 25.598 SH 11 Sep. 2026 Harian
FHLC · FIDELITY COVINGTON TRUST 0,17% 23.486 NS 31 Juli 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,16% 148.331 SH 19 Agu 2026 Harian
REVS · Columbia ETF Trust I 0,15% 2.111 NS 31 Juli 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0,15% 3.646 NS 31 Juli 2026 N-PORT
WSML · iShares Trust 0,14% 6.080 SH 11 Sep. 2026 Harian
IWS · iShares Trust 0,13% 73.404 SH 11 Sep. 2026 Harian
VB · VANGUARD INDEX FUNDS 0,13% 1.102.914 SH 19 Agu 2026 Harian
CURE · Direxion Shares ETF Trust 0,13% 947 NS 31 Juli 2026 N-PORT
DFSV · Dimensional ETF Trust 0,12% 42.976 NS 31 Juli 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,10% 2.764 SH 1 Okt. 2026 Harian
IEUS · iShares Trust 0,10% 5.579 SH 11 Sep. 2026 Harian
IWR · iShares Trust 0,10% 200.615 SH 11 Sep. 2026 Harian
RECS · Columbia ETF Trust I 0,10% 23.999 NS 31 Juli 2026 N-PORT
XOEF · iShares Trust 0,07% 61 SH 11 Sep. 2026 Harian
DFUV · Dimensional ETF Trust 0,06% 41.352 NS 31 Juli 2026 N-PORT
DXUV · Dimensional ETF Trust 0,06% 1.302 NS 31 Juli 2026 N-PORT
DFAC · Dimensional ETF Trust 0,05% 106.991 NS 31 Juli 2026 N-PORT
IVE · iShares Trust 0,04% 79.930 SH 11 Sep. 2026 Harian
IUSV · iShares Trust 0,04% 42.675 SH 11 Sep. 2026 Harian
SCZ · iShares Trust 0,04% 171.786 SH 11 Sep. 2026 Harian
VSS · VANGUARD INTERNATIONAL EQUITY INDEX… 0,04% 174.824 SH 19 Agu 2026 Harian
VOOV · VANGUARD ADMIRAL FUNDS 0,04% 11.139 SH 19 Agu 2026 Harian
DCOR · Dimensional ETF Trust 0,04% 5.545 NS 31 Juli 2026 N-PORT
IWD · iShares Trust 0,04% 108.791 SH 11 Sep. 2026 Harian
CHRI · Global X Funds 0,03% 11 NS 31 Juli 2026 N-PORT
VONV · VANGUARD SCOTTSDALE FUNDS 0,03% 29.579 SH 19 Agu 2026 Harian
PRF · Invesco Exchange-Traded Fund Trust 0,03% 9.073 SH 1 Okt. 2026 Harian
TOPC · iShares Trust 0,03% 32 SH 11 Sep. 2026 Harian
DFSU · Dimensional ETF Trust 0,02% 2.431 NS 31 Juli 2026 N-PORT
XVV · iShares Trust 0,02% 576 SH 11 Sep. 2026 Harian
QVML · Invesco Exchange-Traded Fund Trust … 0,02% 1.252 SH 1 Okt. 2026 Harian
PBP · Invesco Exchange-Traded Fund Trust 0,02% 287 SH 30 Sep. 2026 Harian
RWL · Invesco Exchange-Traded Fund Trust … 0,02% 7.028 SH 1 Okt. 2026 Harian
EGLE · Global X Funds 0,02% 2 NS 31 Juli 2026 N-PORT
IVV · iShares Trust 0,02% 607.129 SH 11 Sep. 2026 Harian
VOO · VANGUARD INDEX FUNDS 0,02% 1.250.774 SH 19 Agu 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,02% 1.530.468 SH 19 Agu 2026 Harian
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 8.168 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 4.112 SH 19 Agu 2026 Harian
ESGV · VANGUARD WORLD FUND 0,02% 11.106 SH 19 Agu 2026 Harian
IWV · iShares Trust 0,02% 14.165 SH 11 Sep. 2026 Harian
IWB · iShares Trust 0,02% 33.863 SH 11 Sep. 2026 Harian
XRMI · Global X Funds 0,02% 41 NS 31 Juli 2026 N-PORT
DFAU · Dimensional ETF Trust 0,02% 9.979 NS 31 Juli 2026 N-PORT
XYLD · Global X Funds 0,02% 2.566 NS 31 Juli 2026 N-PORT
IYY · iShares Trust 0,02% 2.018 SH 11 Sep. 2026 Harian
ITOT · iShares Trust 0,02% 63.582 SH 11 Sep. 2026 Harian
PHDG · Invesco Actively Managed Exchange-T… 0,02% 38 SH 1 Okt. 2026 Harian
PTLC · Pacer Funds Trust 0,02% 2.492 NS 31 Juli 2026 N-PORT
TILT · FlexShares Trust 0,02% 1.620 NS 31 Juli 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 14.645 NS 31 Juli 2026 N-PORT
XYLG · Global X Funds 0,02% 45 NS 31 Juli 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0,02% 182 NS 31 Juli 2026 N-PORT
QDPL · Pacer Funds Trust 0,02% 1.141 NS 31 Juli 2026 N-PORT
XTR · Global X Funds 0,01% 3 NS 31 Juli 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0,01% 332 NS 31 Juli 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0,01% 3.766 NS 31 Juli 2026 N-PORT
IEUR · iShares Trust 0,01% 37.473 SH 11 Sep. 2026 Harian
XCLR · Global X Funds 0,01% 2 NS 31 Juli 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,01% 1.973 SH 1 Okt. 2026 Harian
VGK · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 110.946 SH 19 Agu 2026 Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 77.796 SH 19 Agu 2026 Harian
VEA · VANGUARD TAX-MANAGED FUNDS 0,01% 447.656 SH 19 Agu 2026 Harian
IDEV · iShares Trust 0,01% 52.174 SH 11 Sep. 2026 Harian
IEFA · iShares Trust 0,00% 272.340 SH 11 Sep. 2026 Harian
NEAR · iShares U.S. ETF Trust 0,00% 140.000 SH 9 Sep. 2026 Harian
DFLV · Dimensional ETF Trust 0,00% 377 NS 31 Juli 2026 N-PORT
IXUS · iShares Trust 0,00% 22.623 SH 11 Sep. 2026 Harian
VXUS · VANGUARD STAR FUNDS 0,00% 664.961 SH 19 Agu 2026 Harian
VSGX · VANGUARD WORLD FUND 0,00% 8.805 SH 19 Agu 2026 Harian
VGHY · VANGUARD FIXED INCOME SECURITIES FU… · · 15 Juli 2026 Harian
VCRB · VANGUARD MALVERN FUNDS · · 15 Juli 2026 Harian
VPLS · VANGUARD MALVERN FUNDS · · 15 Juli 2026 Harian
VSDB · VANGUARD MALVERN FUNDS · · 15 Juli 2026 Harian
VGMS · VANGUARD MALVERN FUNDS · · 15 Juli 2026 Harian
ISCB · iShares Trust · 2.146 SH 11 Sep. 2026 Harian
ISCV · iShares Trust · 10.576 SH 11 Sep. 2026 Harian
SMLF · iShares Trust · 18.703 SH 11 Sep. 2026 Harian

CRL Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 23 analis BELI
Target median $322.00 +11,0%
6 26,1% Beli Kuat
11 47,8% Beli
6 26,1% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

15 analis · 2026-10-02

Target rata-rata $305.00 +5,1%

Sekarang Harga saat ini $290.19
Rendah$145.00 Rata-rata$305.00 Tinggi$357.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
CRL $10.02B -70.0 -0.85% -3.6% -4.4% ·
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9% ·
RVTY $10.86B 46.7 3.7% 8.5% 3.3% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TXG $2.08B -46.6 5.2% -6.8% -5.5% 69.0%
TECH $11.03B 60.9 -0.38% 15.0% 9.0% 65.8%
RGEN $9.23B 190.5 16.4% 6.6% 2.4% ·
AVTR $7.82B -14.7 -3.4% -8.1% -8.9% 32.6%
BIO · · · · · ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23
Bio-Techne Ambil Alih Peringkat #477 dari Charles River Laboratories International Nasdaq · 3 bulan lalu Sorotan Panggilan Pendapatan Kuartal I Charles River Laboratories International Yahoo Finance · 4 bulan, 3 minggu lalu Obligasi AS Tokenisasi Mendekati $14 Miliar Saat Circle dan BlackRock Memimpin Pertumbuhan Yahoo Finance · 5 bulan, 2 minggu lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Agu 5, 2026